Oncologic control obtained after radical prostatectomy in men with a pathological Gleason score ≥ 8: A single-center experience

Urologic Oncology: Seminars and Original Investigations

Volumn 29, Issue 6, 2011, Pages 602-607

  Audenet, François ^a,b   Comperat, Eva ^a,b   Seringe, Elise ^a,b   Drouin, Sarah J ^a,b   Richard, François ^a,b   Cussenot, Olivier ^a,b   Bitker, Marc Olivier ^a,b   Rouprêt, Morgan ^a,b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SORBONNE UNIVERSITÉ   (France)

Author keywords

Biochemical recurrence; Gleason score; Outcome; Prostate specific antigen; Prostatic neoplasms; Radical prostatectomy

Indexed keywords

ADULT; AGED; ARTICLE; BIOCHEMISTRY; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; COHORT ANALYSIS; FOLLOW UP; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RETROSPECTIVE STUDY; SURVIVAL RATE;

AGED; DISEASE-FREE SURVIVAL; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 81055126980     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2009.09.011     Document Type: Article

References (33)

1. Jemal A., Siegel R., Ward E., et al. Cancer Statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
2. Cooperberg M.R., Lubeck D.P., Mehta S.S., et al. Time trends in clinical risk stratification for prostate cancer: Implications for outcomes (data from CaPSURE). J Urol 2003, 170:S21-S27.
3. Schroder F.H., Hugosson J., Roobol M.J., et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009, 360:1320-1328.
4. Hammad F.T. Radical prostatectomy. Ann NY Acad Sci 2008, 1138:267-277.
5. Partin A.W., Kattan M.W., Subong E.N., et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997, 277:1445-1451.
6. Montironi R., Mazzuccheli R., Scarpelli M., et al. Gleason grading of prostate cancer in needle biopsies or radical prostatectomy specimens: Contemporary approach, current clinical significance and sources of pathology discrepancies. BJU Int 2005, 95:1146-1152.
7. Han M., Partin A.W., Pound C.R., et al. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 2001, 28:555-565.
8. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol 1999, 17:168-172.
9. Meng M.V., Elkin E.P., Latini D.M., et al. Treatment of patients with high risk localized prostate cancer: Results from cancer of the prostate strategic urological research endeavor (CaPSURE). J Urol 2005, 173:1557-1561.
10. Khan M.A., Partin A.W. Management of high-risk populations with locally advanced prostate cancer. Oncologist 2003, 8:259-269.
11. Lau W.K., Bergstralh E.J., Blute M.L., et al. Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: Influence of concomitant pathological variables. J Urol 2002, 167:117-122.
12. Mian B.M., Troncoso P., Okihara K., et al. Outcome of patients with Gleason score 8 or higher prostate cancer following radical prostatectomy alone. J Urol 2002, 167:1675-1680.
13. Murphy G.P., Busch C., Abrahamsson P.A., et al. Histopathology of localized prostate cancer. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer Stockholm, Sweden, May 12-13, 1993. Scand J Urol Nephrol 1994, 162(Suppl):7-42. Discussion 115-27.
14. Kattan M.W., Eastham J.A., Stapleton A.M., et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998, 90:766-771.
15. Stephenson A.J., Scardino P.T., Eastham J.A., et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol 2005, 23:7005-7012.
16. Albertsen P.C., Hanley J.A., Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005, 293:2095-2101.
17. Khan M.A., Mangold L.A., Epstein J.I., et al. Impact of surgical delay on long-term cancer control for clinically localized prostate cancer. J Urol 2004, 172:1835-1839.
18. Van Poppel H., Joniau S. An analysis of radical prostatectomy in advanced stage and high-grade prostate cancer. Eur Urol 2008, 53:253-259.
19. Partin A.W., Lee B.R., Carmichael M., et al. Radical prostatectomy for high grade disease: A re-evaluation 1994. J Urol 1994, 151:1583-1586.
20. Boorjian S.A., Karnes R.J., Rangel L.J., et al. Impact of prostate-specific antigen testing on the clinical and pathological outcomes after radical prostatectomy for Gleason 8-10 cancers. BJU Int 2008, 101:299-304.
21. Berglund R.K., Jones J.S., Ulchaker J.C., et al. Radical prostatectomy as primary treatment modality for locally advanced prostate cancer: A prospective analysis. Urology 2006, 67:1253-1256.
22. Tefilli M.V., Gheiler E.L., Tiguert R., et al. Role of radical prostatectomy in patients with prostate cancer of high Gleason score. Prostate 1999, 39:60-66.
23. Rodriguez-Covarrubias F., Larre S., De La Taille A., et al. The outcome of patients with pathological Gleason score ≥ 8 prostate cancer after radical prostatectomy. BJU Int 2008, 101:305-307.
24. Manoharan M., Bird V.G., Kim S.S., et al. Outcome after radical prostatectomy with a pretreatment prostate biopsy Gleason score of ≥ 8. BJU Int 2003, 92:539-544.
25. Messing E.M., Manola J., Yao J., et al. Immediate vs. deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006, 7:472-479.
26. Humphrey P., et al. Prostate pathology 2003, 138-374. ASCP Press, Chicago.
27. Grossfeld G.D., Chang J.J., Broering J.M., et al. Under staging and under grading in a contemporary series of patients undergoing radical prostatectomy: Results from the Cancer of the Prostate Strategic Urologic Research Endeavor database. J Urol 2001, 165:851-856.
28. Grossfeld G.D., Latini D.M., Lubeck D.P., et al. Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer. J Urol 2003, 169:157-163.
29. Evans A.J., Henry P.C., Van der Kwast T.H., et al. Interobserver variability between expert urologic pathologists for extraprostatic extension and surgical margin status in radical prostatectomy specimens. Am J Surg Pathol 2008, 32:1503-1512.
30. Stephenson A.J., Kattan M.W., Eastham J.A., et al. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol 2009, 27:4300-4305.
31. Roupret M., Hupertan V., Comperat E., et al. Cross-cultural validation of a prognostic tool: Example of the Kattan preoperative nomogram as a predictor of prostate cancer recurrence after radical prostatectomy. BJU Int 2009, 104:813-818.
32. Kane C.J., Presti J.C., Amling C.L., et al. Changing nature of high risk patients undergoing radical prostatectomy. J Urol 2007, 177:113-117.
33. Do T.M., Parker R.G., Smith R.B., et al. High-grade carcinoma of the prostate: A comparison of current local therapies. Urology 2001, 57:1121-1127.